Test Your Knowledge: ASCO 2020 Quiz Sep 11, 2020 It’s no question that advancements in lung cancer treatment were in the spotlight at ASCO 2020. Are you caught up? Take our quiz and see how you compare with your colleagues! 1) The Phase 3 CASPIAN Trial met its primary endpoint of overall survival, reducing the risk of death by 27% in newly diagnosed patients with ES-SCLC after more than 2 years by combining durvalumab (Imfinzi) with what:*durvalumab + tremelimumabdurvalumab + tremelimumab + etoposide cisplatin/carboplatindurvalumab + etoposide cisplatin/carboplatindurvalumab + placebo2) At 18 months, of the patients who received durvalumab plus chemotherapy vs placebo in the CASPIAN Phase 3 Trial, 34% were alive vs 25%, respectively.*TrueFalse3) What trial showed that adjuvant treatment with osimertinib (Tagrisso) reduced the risk of disease recurrence or death by 79% in patients with stage IB to IIIA EGFR-mutant NSCLC?*ADAURAKEYNOTECHECKMATECITYSCAPE4) Phase 3 CHECKMATE-227 found that patients with advanced NSCLC treated with nivolumab (Opdivo) plus ipilimumab (Yervoy) vs chemotherapy had a 21% reduced risk of death after a median follow up of about*13 months25 months43 months51 months5) Data from phase 3 KEYNOTE-604 showed patients with ES-SCLC who received pembrolizumab (Keytruda) with chemotherapy improved overall survival vs chemotherapy and placebo.*TrueFalse